NAMS

NEWAMSTERDAM PHARMA COMPANY

NAMS·N62509109·US·Common Stock·Healthcare - Biotechnology-Activist

NAMS (NEWAMSTERDAM PHARMA COMPANY) is held by 94 institutional investors as of Q1 2026. Largest holders: Capital World Investors ($355.6M), RA CAPITAL MANAGEMENT, L.P. ($305.7M), FMR LLC ($280.6M). Net institutional sentiment: Mixed.

94
Holders
(8 Elite)
$2.4B
Total Value
55% (104)
Consensus
57 buying - 47 selling
13F: Insider & Congress:
NAMSSmart Money Verdict
View all
Held by 94 funds
8 elite
Who's Trading
InsiderKFKooij Louise FrederikaSell $1.2MJun 22, 2026
InsiderKFKooij Louise FrederikaSell $9KJun 22, 2026
ActivistCapital World InvestorsCapital World Investors10.4%Jun 4, 2026
ActivistBIBCLS Fund III Investments, LP1.8%May 14, 2026
ActivistFMR LLCFMR LLC7.6%May 6, 2026
InsiderLGLANGE LOUIS GSell $1.3MMar 11, 2026
InsiderLGLANGE LOUIS GSell $14KMar 11, 2026
InsiderKPKastelein Johannes Jacob PieterSell $3.1MMar 9, 2026
InsiderLGLANGE LOUIS GSell $829KMar 6, 2026
InsiderKPKastelein Johannes Jacob PieterSell $2.9MMar 6, 2026
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
11.1M(+11.3%)$355.6M0.0%+50.28%
35
Unchanged
9.6M$305.7M3.2%+149.93%
0
Increased
8.8M(+36.7%)$280.6M0.0%+28.57%
40
Increased
5.1M(+1.6%)$163.8M0.0%+31.37%
31
Unchanged
4.2M$134.6M0.4%+219.51%
0
Unchanged
3.1M$98.3M2.9%+25.46%
0
Increased
2.8M(+2.0%)$90.6M0.3%+57.24%
36
Decreased
2.8M(-21.2%)$88M0.1%+37.14%
0
Decreased
2.3M(-3.5%)$72.3M0.0%+55.59%
0
New
2.2M$70.5M0.3%+15.95%
49
Increased
2.2M(+15.4%)$70M0.8%+44.37%
48
Increased
1.9M(+12.8%)$62.3M0.0%+21.55%
33
Decreased
1.4M(-30.1%)$46.1M0.0%+37.73%
0
Decreased
1.2M(-7.8%)$42.1M0.0%+42.77%
0
Decreased
1.1M(-21.3%)$35.4M0.1%+91.50%
0
Decreased
1M(-3.9%)$33.4M0.1%+1.50%
0
Increased
957,442(+440.9%)$30.6M0.0%+12.97%
46
Increased
886,616(+4.3%)$28.4M0.0%+28.57%
30
Increased
847,089(+84.4%)$27.1M0.0%+36.37%
44
Increased
837,005(+14.7%)$26.8M0.0%+57.61%
33

Showing 1-20 of 111

1 / 6

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used